Breaking News

PCI Acquires Biotec

Expands clinical trial and cold chain services

By: Kristin Brooks

Managing Editor, Contract Pharma

PCI has acquired Biotec Services International, a provider of clinical trial services and temperature controlled pharma services headquartered in Bridgend, Wales. The acquisition expands PCI’s presence in the UK/EU to support global investigational studies with additional packaging, storage and distribution capacity, as well as consulting services for clinical trial supplies.
 
Biotec recently expanded its facilities with additional packaging, storage and distribution. Biotec supports global projects across a range of temperature conditions including 2 – 8°C, -20°C, -40°C, -80°C, and specialization in products requiring -196°C. The expansion quadrupled the company’s capacity to store, package and ship Cold Chain products, and includes a second purpose built facility for the storage of Advanced Therapeutic Medicinal Products (ATMP) at -196°C. 
 
PCI also recently acquired Penn Pharma, adding pharma development and contained manufacturing services, commercial packaging, and lab services. Also, following its acquisition of AndersonBrecon in 2013, PCI now represents 16 facilities across North America and Europe, employing more than 2,900 associates.
 
“The expertise of the team at Biotec is a natural fit for the strategic direction of our business,” said Bill Mitchell, chief executive officer and president of PCI. “We are focused on providing our clients an expert partner in the development, clinical investigation, and ultimate commercialization of their lifesaving therapies. Adding Biotec, as well as the drug development and manufacturing expertise of Penn Pharma, truly positions PCI to provide that substantial added value to our clients.  I am very excited about the depth of the solutions we can provide our clients to address their daily challenges in bringing new products to successful commercialization.”
 
Fiona Withey, chief executive officer of Biotec Services, said, “Biotec has grown as a result of our team’s expertise in temperature-controlled clinical trial supply services, our innovative technology solutions, our flexibility, and our commitment to customer service. In a recent client survey, our clients told us that we should continue to do what we are doing, but should aim to develop the scope and global presence of our offering.  Joining the PCI family allows us to deliver a truly global service to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters